Living the Mission in Health and Business to Achieve Health Equity

As health disparities come under the spotlight, the urgency to achieve health equity in the healthcare sector intensifies. With the industry at a crossroads, a recent study funded by the NIH highlighted the staggering economic impact of these disparities, revealing an estimated cost of $451 billion to the economy in 2018 alone. That figure could jump as high as $1 trillion annually in spending by 2040 if the problem is left unsolved.

Are leading healthcare organizations stepping up to address this challenge? If so, what innovative strategies are reshaping the future to achieve health equity?

On Healthcare Rethink, host Brian Urban sat down with Sameer Kokan, VP and Chief of Staff to the CEO at Point32Health. This episode explores Point32Health’s transformative approaches to health equity.

Urban and Kokan’s discussion includes the following:

  • The significance of health equity in modern healthcare and its economic implications
  • The industry’s response and commitment to addressing health disparities
  • The role of innovative strategies and public accountability in driving health equity initiatives

With a rich background spanning various facets of healthcare, Sameer Kokan offers invaluable insights. From aspiring to be a physician to pivoting towards the business side of healthcare, Kokan’s diverse experiences mark the path of his journey. At Point32Health, he champions the cause of health equity, emphasizing the need for collaborative and data-driven approaches.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…